Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
Study identifier:D5660C00017
ClinicalTrials.gov identifier:NCT03394144
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with Advanced Solid Malignancies
Medical condition
Advanced solid malignancies
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD9150, Durvalumab
Sex
All
Actual Enrollment
11
Study type
Interventional
Age
20 Years - 120 Years
Date
Study Start Date: 30 Jan 2018
Primary Completion Date: 12 Apr 2019
Study Completion Date: 12 Apr 2019
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verification:
Verified 01 Mar 2021 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: C1:AZD9150, C2:AZD9150+Durvalumab After confirmed safety with Cohort 1, Cohort 2 will open | Drug: AZD9150, Durvalumab After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT |
